Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

Trial arms side by side.

One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.

ClassNone selected

No arms selected. Choose a drug, an arm, or a preset.

Each arm uses its closest stored timepoint inside the window.

Cross-trial values

value

Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.

No selected arm has this endpoint inside the time window.

Show as table
ArmTrialPhasePopulationnComparatorTimepointEstimandAssessorValue

Not shown

Every selected arm is drawn.

20 of 25 arms with a reported figure. Choose arms to narrow the chart.

Drug, trialPopulationDoseEstimandComparatorORR, %mPFS, monthsmOS, monthsHazard ratioOther
Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source)Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort)R/M ACC, evaluable (n = 45)Phase 1 doses (not stated in source)Single armn/robjective response rate: 35.6%, ASCO 2026n/rn/rn/rdisease control rate: 82.2%, ASCO 2026median duration of response: 7.4 months, ASCO 2026
Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source)Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort)ACC with solid histology or high-grade transformation (n = 32, post hoc)Phase 1 doses (not stated in source)Single armn/robjective response rate: 46.9%, ASCO 2026; post hocmedian progression-free survival: 7.8 months, ASCO 2026; post hocn/rn/rmedian duration of response: 6.4 months, ASCO 2026; post hoc
Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source)Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort)ACC safety population (n = 48)Phase 1 doses (not stated in source)Single armn/rn/rn/rn/rn/rn/r
RGT-61159 at or below RP2D (mixed doses)RGT-61159 Phase 1a/bR/R ACC, evaluable (n = 39)at or below RP2D (mixed doses)Single armn/rpartial responses: 3 patients (of 39), ASCO 2026; 2 confirmed, 1 pendingn/rn/rn/rdisease control rate: 84.6%, ASCO 2026, preliminary
REM-422 24 mgARIAR/M ACC, MYB biomarker positive at RP2D (n = 7)24 mgSingle armn/robjective response rate: 43%, cutoff 01.07.2026, Abstract 6009 states 42% (3 of 7)n/rn/rn/rdisease control rate: 100%, ASCO 2026
REM-422 12 to 48 mgARIAbiomarker-positive R/M ACC (n = 30)12 to 48 mgSingle armn/rn/rn/rn/rn/rany target-lesion reduction: 70%, cutoff 01.07.2026target-lesion shrinkage of 20% or more: 47%, cutoff 01.07.2026
REM-422 24 mgARIAall patients at RP2D (n = 15)24 mgSingle armn/rn/rn/rn/rn/rn/r
Osugacestat (AL101, BMS-906024) 4 mgACCURACYR/M ACC with NOTCH1 to 4 activating mutation (n = 45)4 mgSingle armn/rresponders (CR or PR): 3 patients (of 45), final, results posted 01.31.2024n/rmedian overall survival: 9.3 months, finaln/rn/r
Osugacestat (AL101, BMS-906024) 6 mgACCURACYR/M ACC with NOTCH activating mutation (n = 42)6 mgSingle armn/rresponders (CR or PR): 2 patients (of 42), finaln/rmedian overall survival: 9.4 months, finaln/rn/r
Lenvatinib (off Label) 24 mgLenvatinib MSK Phase 2progressive R/M ACC (n = 32 evaluable)24 mgSingle armn/robjective response rate: 15.6%, primary analysismedian progression-free survival: 17.5 months, 8 progression eventsn/rn/rn/r
Lenvatinib (off Label) 24 mgACC-LEN14R/M salivary ACC (n = 26 evaluable)24 mgSingle armn/robjective response rate: 11.5%, primary analysismedian progression-free survival: 9.1 months, primary analysismedian overall survival: 27 months, primary analysisn/rn/r
Lenvatinib (off Label) not stated in sourceLenvatinib + pembrolizumabprogressive R/M ACC (n = 17 evaluable)not stated in sourceSingle armn/robjective response rate: 6%, ASCO 2023 (search record)n/rn/rn/rn/r
Axitinib (off Label) 5 mgAxitinib vs observation (randomized Phase 2)R/M ACC with progression within 9 months (n = 60 total)5 mgITTobservationobjective response rate: 0%, primary analysismedian progression-free survival: 10.8 months, primary analysis6-month progression-free survival: 73%, 6 monthsn/rprogression-free survival hazard ratio vs observation: 0.25 HR, as reported in ESMO-EURACAN guidelinedisease control rate: 100%, primary analysis
Axitinib (off Label) noneAxitinib vs observation (randomized Phase 2)R/M ACC with progression within 9 monthsnoneITTn/rn/rmedian progression-free survival: 2.8 months, primary analysis6-month progression-free survival: 23%, 6 monthsmedian overall survival: 27.2 months, axitinib median not reached; P 0.226n/rdisease control rate: 51.9%, primary analysis
Axitinib (off Label) axitinib 5 mg twice daily + avelumabAxitinib + avelumab Phase 2 (MD Anderson)R/M ACC (n = 28 evaluable)axitinib 5 mg twice daily + avelumabSingle armn/rconfirmed objective response rate: 18%, primary analysismedian progression-free survival: 7.3 months, primary analysismedian overall survival: 16.6 months, primary analysisn/rn/r
Axitinib (off Label) as aboveAxitinib + avelumab Phase 2 (MD Anderson)ACC-I (exploratory biomarker analysis of 28 patients)as aboveSingle armn/rn/rmedian progression-free survival: 1.8 months, updated analysis; exploratoryn/rn/rn/r
Axitinib (off Label) as aboveAxitinib + avelumab Phase 2 (MD Anderson)ACC-II (exploratory)as aboveSingle armn/rn/rmedian progression-free survival: 11.4 months, updated analysis; HR 0.14 vs ACC-In/rn/rn/r
Rivoceranib 700 mgRivoceranib Phase 2R/M ACC (n = 80; 72 evaluable)700 mgSingle armn/robjective response rate (investigator): 15.3%, primary analysisobjective response rate (independent review): 9.7%, primary analysismedian progression-free survival: 9 months, primary analysisn/rn/rmedian duration of response (investigator): 14.9 months, primary analysis
Amivantamab not stated in sourceAmivantamab in ACCACC (n = 21)not stated in sourceSingle armn/rresponders: 1 patients (of 21), results posted 05.08.2026median progression-free survival: 4.6 months, results posted 05.08.2026n/rn/rn/r
Regorafenib (off Label) not stated in sourceRegorafenib in ACCprogressive R/M ACC (n = 38)not stated in sourceSingle armn/rresponders (CR or PR): 1 patients (of 38), results posted 09.10.2025n/rn/rn/rn/r

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.